Hims Daily (Apr 22, 2025)
Leadership shakeup: COO Melissa Baird to step down after 7 years
Stock Price: $25.37
Today: -$0.47 (-1.82%)
Year-to-date: +$1.19 (+4.92%)
Quarter-to-date: -$4.18 (-14.15%)
🚨 NEW: Our first Q2 Revenue Prediction drops later this week — and our FINAL Q1 estimate lands next week. (We were within 1% last quarter.) Upgrade for access, just $20/mo or $200/yr.
What’s Happening
HIMS slid 1.9% today. It opened at $26.49 before knifing to an intraday low of $25.13 mid-morning, and never reclaimed its morning highs even as the Nasdaq ripped +3%
Even though the indices reversed on late‑day tariff deal optimism, HIMS barely budged, underscoring heavy short interest (~30%) and sentiment fatigue
Long‑time COO Melissa Baird will exit to an advisory role once a successor is hired, revealed an 8‑K filed after-hours on Monday. Baird followed up the announcement with a post on LinkedIn.
Andrew Dudum (CEO) responded simply: “#goat”
Jack Abraham (co-founder) responded: “Congrats on an epic run, Melissa! It was so amazing having the opportunity to work with you. Thank you for your incredible contributions and couldn’t be more excited for what comes next for you!”
Cool to see the co-founders congratulating Baird on an outstanding 7 years
The CTO role is no longer listed on Hims’ public careers page. The position was originally posted on March 21, 2025, but it’s unclear exactly when it was taken down — it could have been removed at any point over the past month. I only noticed the change today.
The FDA issued a nationwide warning to pharmacies about compounded topical finasteride. Although not specifically directed at HIMS, the headline revived anxieties around the company’s broader compounding strategy and the possibility Novo Nordisk could sue now that the semaglutide “cool‑off” window has expired.
Yesterday, Hims (No. 6) and Hers (No. 9) iOS medical‑app rankings hit two‑month highs
More on this in our weekly data tracker update, later this week 🔥
Catalysts
April 22 (today) - 503As must cease production of commercial-dose semaglutide
May 5 - Q1 earnings after the bell
White House clarification on pharma tariffs
Potential legal action by NVO against compounders
Upcoming OFA vs. FDA case on semaglutide
Potential for partnership with NVO and/or LLY to sell lower-priced GLP-1s
Top Tweets
